These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT Ma M; Yang Y; Du G; Dai Y; Zhu X; Wang W; Xu H; Zhang J; Zheng L; Zou F; Yang H; Liu B; Liu W; Ye L; Zhang R; Tian J Eur J Med Chem; 2022 Apr; 234():114246. PubMed ID: 35279606 [TBL] [Abstract][Full Text] [Related]
4. Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease. McFarland K; Price DL; Bonhaus DW Behav Pharmacol; 2011 Oct; 22(7):681-92. PubMed ID: 21921840 [TBL] [Abstract][Full Text] [Related]
5. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417 [TBL] [Abstract][Full Text] [Related]
6. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis. Kianirad Y; Simuni T Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967 [TBL] [Abstract][Full Text] [Related]
7. A new class of 5-HT Casey AB; Mukherjee M; McGlynn RP; Cui M; Kohut SJ; Booth RG Br J Pharmacol; 2022 Jun; 179(11):2610-2630. PubMed ID: 34837227 [TBL] [Abstract][Full Text] [Related]
8. Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin. Lyons KE; Pahwa R; Hermanowicz N; Davis T; Pagan F; Isaacson S Expert Rev Clin Pharmacol; 2019 Jul; 12(7):681-691. PubMed ID: 31159608 [No Abstract] [Full Text] [Related]
9. Pimavanserin for the treatment of Parkinson's disease psychosis. Chendo I; Ferreira JJ Expert Opin Pharmacother; 2016 Oct; 17(15):2115-24. PubMed ID: 27609312 [TBL] [Abstract][Full Text] [Related]
10. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin. Majlath Z; Obal I; Vecsei L CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624 [TBL] [Abstract][Full Text] [Related]
11. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis. Hacksell U; Burstein ES; McFarland K; Mills RG; Williams H Neurochem Res; 2014 Oct; 39(10):2008-17. PubMed ID: 24682754 [TBL] [Abstract][Full Text] [Related]